title: [Therapeutic efficacy of imatinib mesylate (glivec) in chronic phase of myeloid leukemia].
abstract: OBJECTIVE
  To evaluate efficacy and tolerance of glivek in chronic myeloid leukemia (CML) in patients who failed interferon-alpha (If-a) preparations.
  
  
  METHODS
  79 patients in a chronic phase of Ph + CML with hematological and cytogenetic resistance or intolerance of If-a. The response to glivec was assessed by achievement of a complete hematological remission and the cytogenetic effect (the degree of reduction of cell clone Ph+ in bone marrow). Tolerance and safety of the drug was studied by monthly standard clinicohematological tests.
  
  
  RESULTS
  Not only a hematological remission (92.4%), but also partial (46.8%) or complete (27.8%) elimination of BCR-ABL +/- cells were achieved after 12 months of the treatment. Glivec was well tolerated. Hematological toxicity primarily as neutropenia and thrombocytopenia were observed in 54.4 and 42% patients, respectively. Neutropenia of the third degree which made impossible to continue the treatment was observed in 29.1% patients; throbocytopenia of the third degree was registered in 16.5% patients. Among most frequent non-hematological side effects there were moderate edema, nausea, leg muscle convulsions, weight gain, arthralgias, skin eruption. All the complications were transient, were managed in all cases with only a short-time discontinuation of glivec therapy.
  
  
  CONCLUSIONS
  High activity of glivec at early stages of CML allows using this drug as a first-line therapy in patients with CML.
authors.forename: A G
authors.initials: AG
authors.lastname: Turkina
authors.forename: N D
authors.initials: ND
authors.lastname: Khoroshko
authors.forename: G A
authors.initials: GA
authors.lastname: Druzhkova
authors.forename: B V
authors.initials: BV
authors.lastname: Zingerman
authors.forename: E S
authors.initials: ES
authors.lastname: Zakharova
authors.forename: E Iu
authors.initials: EIu
authors.lastname: Chelysheva
authors.forename: O Iu
authors.initials: OIu
authors.lastname: Vinogradova
authors.forename: E V
authors.initials: EV
authors.lastname: Domracheva
authors.forename: A V
authors.initials: AV
authors.lastname: Zakharova
authors.forename: L G
authors.initials: LG
authors.lastname: Kovaleva
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D001854:Bone Marrow Cells / Q000187:drug effects / Q000378:metabolism; D020732:Cytogenetic Analysis; D018572:Disease-Free Survival; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D007621:Karyotyping; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl